Moreover, we found that the HSP70/HSF1 axis is a druggable target in CLL cells considering that neoplastic B cells underwent apoptosis when treated with HSP70/HSF1 axis inhibitors (i.e., fisetin, VER-155008, zafirlukast and KRIBB-11) [98]. The gene discussed is HSF1; the disease is B-cell chronic lymphocytic leukemia.